Picard Medical Inc (PMI)

Welcome aboard, it had gotten beaten down for no reason and is just now regaining it's footing.

Enjoy the ride but hold on cause it can get rough from time to time.

Bought in the AM premarket.

This is a possible massive company with the recent news.

Massive volume today and maintaining 60% gains on the day with over 800 million shares traded.

There has to be a breakout in the future - let's hope the retrace if over and the rocket is fueled up.

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures —

— Advancing second-generation Emperor TAH development toward a fully implantable system —

TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company’s next-generation Emperor Total Artificial Heart (“Emperor TAH” or “Emperor”) Platform at the University of Arizona and Banner University Medical Center in Tucson.

The animal study evaluated the latest iteration of the Emperor TAH, an electromechanically actuated system designed to build upon the established blood-contacting architecture and extensive clinical experience of the SynCardia Total Artificial Heart (“STAH”) while advancing patient mobility and supporting the future development of a fully implantable artificial heart system.

Initial preclinical data from the first-generation Emperor TAH, completed in late 2025, were subsequently presented at the American College of Cardiology and at the International Society for Heart & Lung Transplantation 2026 conferences. Compared to the previous generation device, the latest iteration incorporates an independent dual motor ventricular system enabling side-specific control of systemic and pulmonary circulation. The system is designed to support physiologic responsiveness while preserving the underlying pumping principles and autoregulatory characteristics of the STAH.

Three acute implant procedures were successfully completed. Across all study procedures, the Emperor TAH demonstrated stable hemodynamic support with observations consistent with physiologic autoregulatory behavior. No device-related intraoperative failures were observed.

“This animal study demonstrated the Emperor’s capability to provide stable full circulatory support in a large animal model and generated important data supporting continued preclinical and translational development activities,” said Andre Simon, MD-PhD, Vice President of Clinical Affairs.

“The independent ventricular architecture operated as intended under study conditions,” said Matthew Schuster, Chief Operating Officer of Picard Medical and inventor of the Emperor. “These studies further validated the design and will support ongoing system optimization and future testing.”

“These studies mark another important milestone toward our goal of a fully implantable artificial heart,” said Patrick Schnegelsberg, Chief Executive Officer of Picard Medical. “The Emperor TAH is designed to build on decades of clinical experience from the SynCardia platform, with the goal of improving patient mobility and quality of life.”

The studies were conducted in collaboration with researchers and surgical teams at The University of Arizona and Banner University Medical Center Tucson.

The Emperor TAH is being developed as a fully implantable artificial heart platform intended to provide long-term circulatory support for patients with advanced biventricular heart failure without the need for external pneumatic drivers. The Emperor TAH is currently under development and has not received FDA approval or clearance.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

PMI.......................https://stockcharts.com/sc3/ui/?s=PMI&p=W&b=5&g=0&id=p86431144783

PMI............................p/m

$PMI junk

Junk

Junk

Added on the offering smackdown.

Today's PR
Picard Medical / SynCardia Recognizes Banner Health as Global Leader and Supporter in the Advancement of Total Artificial Heart Technology
Banner Health has performed more than 50 SynCardia Total Artificial Heart implants, establishing itself as a leading center in total artificial heart therapy
TUCSON, Ariz., April 30, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today recognized Banner Health’s support in bridge-to-transplant cases, following its recent announcement highlighting the health system’s experience and global leadership in total artificial heart therapy. Specifically, Banner Health, one of the nation’s largest fully integrated nonprofit health systems, reported that its team has performed more than 50 implants of the SynCardia Total Artificial Heart (“STAH”), representing one of the busiest programs globally.

Banner Health’s program is led by Francisco Arabia, M.D., and is part of its broader advanced heart failure and transplant services. According to Banner Health, its Advanced Heart Failure Program has contributed to the development of clinical practices across patient selection, surgical technique, and post-implant management.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, commented, “Banner Health’s experience with more than 50 SynCardia Total Artificial Heart implants reflects a significant level of clinical expertise in the management of patients with advanced biventricular heart failure. Their program, which receives referrals from medical centers worldwide, has contributed to the growing body of clinical experience supporting the use of total artificial heart therapy in bridge-to-transplant patients.”

“Reaching this procedure milestone represents our unwavering commitment to advancing cardiac care and improving outcomes for patients with end-stage heart failure,” said Francisco Arabia, MD, physician executive of the Banner – University Medicine Advanced Heart Failure Program and Professor of Cardiothoracic Surgery, University of Arizona College of Medicine - Tucson. “This achievement reflects our team's dedication and the trust that medical centers worldwide place in our expertise. Today we're bridging patients to transplant, but together with our innovative partners, we’re closing the gap between today's challenges and tomorrow's solutions in cardiac care.”

Total artificial heart therapy is indicated as a bridge to transplant for patients with irreversible biventricular heart failure who are not candidates for isolated left ventricular assist device support. By replacing both ventricles and all four native heart valves, the STAH is designed to restore circulation and maintain hemodynamic stability while patients await donor heart availability.

More than 6 million adults in the United States are living with heart failure, and the demand for donor hearts continues to exceed supply.

To date, more than 2,100 STAH implants have been performed worldwide in patients with advanced biventricular heart failure, with the longest reported duration of support exceeding eight years.

Picard Medical continues to support transplant centers in the United States and internationally in the use of the STAH. The Company is also advancing development of the Emperor Total Artificial Heart, a fully implantable, next-generation device designed to expand access to long-term mechanical circulatory support without the need for external pneumatic drivers.

About Banner Health

Banner Health's mission is to make health care easier, so life can be better. As one of the nation's largest fully integrated nonprofit health systems, Banner Health is pioneering a sustainable care model that prioritizes prevention, manages chronic disease, and reduces health spending – succeeding when patients stay healthy, not when they get sick. Banner Health operates 33 hospitals and more than 400 sites across six states, delivering seamless care from primary to quaternary medicine, including health insurance, physician networks, world-renowned specialty services, and behavioral health. Accountable to the communities it serves, Banner Health reinvests into advancing care, research, and facilities, providing more than $1 billion each year in community benefit. Through its partnership with the University of Arizona, Banner Health drives clinical discoveries across more than 800 trials and trains more than 1,300 residents and fellows annually. Headquartered in Arizona, Banner Health serves Arizona, California, Colorado, Nebraska, Nevada, and Wyoming. Banner Health hospitals are consistently ranked among Arizona's top-performing by U.S. News & World Report. For more information, visit bannerhealth.com/about.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Heck, at .45 I'll buy a ticket - most of these ambulance chasers lose when it comes time to show proof of their claims.

Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMIMarch 2, 2026 3:47 AM
PR Newswire (US)

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Picard Medical, Inc. ("Picard" or "the Company") (NYSE American: PMI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  September 2, 2025 to October 31, 2025 DEADLINE: April 3, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Picard and its insiders benefited from a stock manipulation scheme designed to inflate its share price. Based on these facts, Picard's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/picard-medical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--pmi-302700599.htmlSOURCE DJS Law Group LLP

Original: Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMI

Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMIFebruary 23, 2026 4:13 AM
PR Newswire (US)

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Picard Medical, Inc. ("Picard" or "the Company") (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: September 2, 2025 to October 31, 2025 DEADLINE: April 3, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Picard and its insiders benefited from a stock manipulation scheme designed to inflate its share price. Based on these facts, Picard's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT: 
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/picard-medical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--pmi-302694334.htmlSOURCE DJS Law Group LLP

Original: Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMI

PMI.............................https://stockcharts.com/sc3/ui/?s=PMI&p=W&b=5&g=0&id=p86431144783

$PMI: Its working now......... damnnnnnnnn 3.30

Whatta PM surger............. big boost from $1.60 yesterday


GO $PMI

Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMIFebruary 9, 2026 3:39 AM
PR Newswire (US)

LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Picard Medical, Inc. ("Picard " or "the Company") (NYSE American: PMI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: September 2, 2025 to October 31, 2025 DEADLINE: April 3, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Picard and its insiders benefited from a stock manipulation scheme designed to inflate its share price. Based on these facts, Picard's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. SchwartzDJS Law Group274 White Plains Road, Suite 1Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/picard-medical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--pmi-302682269.htmlSOURCE DJS Law Group LLP

Original: Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMI

Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – PMIFebruary 5, 2026 7:50 AM
Business Wire
The DJS Law Group reminds investors of a class action lawsuit against Picard Medical, Inc. (“Picard” or “the Company”) (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.


Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.


CLASS PERIOD: September 2, 2025 to October 31, 2025


DEADLINE: April 3, 2026


CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Picard and its insiders benefited from a stock manipulation scheme designed to inflate its share price. Based on these facts, Picard’s public statements were false and materially misleading throughout the class period.


If you are a shareholder who suffered a loss, contact us to participate.


WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.


Join the case to recover your losses.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205165866/en/
David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com


Original: Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – PMI

Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMIFebruary 5, 2026 4:05 AM
PR Newswire (US)

LOS ANGELES, Feb. 5, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Picard Medical, Inc. ("Picard " or "the Company") (NYSE American: PMI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  September 2, 2025 to October 31, 2025 DEADLINE: April 3, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Picard and its insiders benefited from a stock manipulation scheme designed to inflate its share price. Based on these facts, Picard's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/picard-medical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--pmi-302679778.htmlSOURCE DJS Law Group LLP

Original: Picard Medical, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PMI

PMI. Bio beast. The first artificial heart

PMI......................................https://stockcharts.com/sc3/ui/?s=PMI&p=W&b=5&g=0&id=p86431144783